CITIUS ONCOLOGY, INC. - 8-K Filing
Citius Oncology announced Phase 1 clinical data from an investigator-initiated study of LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026. The trial showed a 24% overall response rate among 21 efficacy-evaluable patients and median progression-free survival of 20.5 months in those achieving clinical benefit. A Phase 2 expansion study is being planned. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CTOR